Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1338265
PUBLISHER: BCC Research | PRODUCT CODE: 1338265
Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends
PUBLISHED:
PAGES: 122 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Highlights:
The global acute myeloid leukemia (AML) treatments market should reach $6.1 billion by 2028 from $3.8 billion in 2023 at a compound annual growth rate (CAGR) of 10.0% for the forecast period of 2023 to 2028.
Targeted therapy segment of the global AML treatments market is expected to grow from $3.5 billion in 2023 to $5.6 billion in 2028 at a CAGR of 9.9% for the forecast period of 2023 to 2028.
Anthracycline drugs segment of the global AML treatments market is expected to grow from $141.3 million in 2023 to $239.8 million in 2028 at a CAGR of 11.2% for the forecast period of 2023 to 2028.
Report Scope:
This report aims to comprehensively study the market size of AML and treatments for a global market. Current and historical market revenues can be estimated based on treatment type, route of administration, end use, distribution channel and region.
Report Includes:
- 42 data tables and 57 additional tables
- An overview of the global market for acute myeloid leukemia (AML) treatment
- Analyses of global market trends, with data from 2020 to 2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
- Highlights of the market potential and characterization of AML market based on treatment type, route of administration type, end-users, distribution channel, region
- Coverage of various risk factors associated with AML, such as exposure to radiation or chemicals, genetic disorders, and weakened immune system
- Description of major treatment options for AML such as, chemotherapy, targeted therapy, and stem cell transplantation
- Information on recent mergers, acquisitions, collaborations, agreements, partnerships, product launches, and expansions in the market and a relevant patent analysis
- Detailed company profiles of major players in the market of the industry, including AbbVie, Daiichi Sankyo, GlaxoSmithKline PLC, Pfizer Inc. and Servier
Product Code: PHM276A
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Methodology
- Information Sources
- Primary Research
- Secondary Research
- Geographic Breakdown
Chapter 2 Summary and Highlights
- Market Outlook
- This Report Highlights
Chapter 3 Market Overview and Definitions
- Overview
- Acute Myeloid Leukemia
- The Global Regulatory Structure for AML
- Pricing and Reimbursement for AML
- Therapies/Drugs to Treat AML
- FLT3 Inhibitors
- IDH Inhibitors
- Apoptosis Stimulants
- DNA Methylation Inhibitors
- DNA Intercalators
- Angiogenesis Inhibitors
- DNA Synthesis Inhibitors
Chapter 4 Market Dynamics
- Market Drivers
- Growing Elderly Population
- Increasing Incidence and Prevalence
- Advancements in Molecular Diagnostics
- Minimal Residual Disease (MRD) Monitoring
- Gene Expression Profiling
- Fusion Gene Detection
- Liquid Biopsies
- R&D
- Regulatory Environment
- Personalized Medicine
- Collaborative Efforts
- Patient Advocacy and Awareness
- Market Opportunity
- Strategic Initiative
- Market Restraints
- High Costs
- Limited Treatment Options
- Treatment-related Toxicity and Adverse Effects
- Regulatory and Reimbursement Challenges
Chapter 5 Impact of COVID-19
- Introduction
- COVID-19 Impact on AML Treatments
Chapter 6 Market Breakdown by Region
- Market Overview and Discussion
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Market Breakdown by Treatment Type
- Market Overview and Discussion
- Targeted Therapy
- Anthracycline Drugs
- Other Chemotherapies
- Targeted Therapy
- Anthracycline Drugs
- Other Chemotherapies
Chapter 8 Market Breakdown by Route of Administration
- Market Overview and Discussion
- Intravenous (IV) Administration
- Oral Administration
- Intravenous (IV) Administration
Chapter 9 Market Breakdown by Product
- FLT3 Inhibitors
- Apoptosis Stimulants
- Angiogenesis Inhibitors
- DNA Methylation Inhibitors
- DNA Synthesis Inhibitors
- DNA Intercalators
Chapter 10 ESG Development
- Introduction
- Environment
- Governance
Chapter 11 Emerging Trends and Technologies
- Introduction
Chapter 12 Competitive Landscape
- Overview
- Industry Scenario
- Company Shares
Chapter 13 Patent Analysis
- Patent Analysis by Manufacturer
Chapter 14 Pipeline Analysis
- Clinical Trail Scenario
Chapter 15 M&A and Venture Funding Outlook
- Introduction
Chapter 16 Company Profiles
- ABBVIE
- AMGEN INC.
- ASTELLAS PHARMA INC.
- BAYER AG
- BIOGEN
- BRISTOL MYERS SQUIBB
- DAIICHI SANKYO CO. LTD.
- GILEAD SCIENCES INC.
- GLAXOSMITHKLINE PLC
- MERCK & CO. INC.
- NOVARTIS
- PFIZER INC.
- SANOFI
- SERVIER LABORATORIES
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 17 Appendix: Acronyms
Product Code: PHM276A
List of Tables
- Summary Table : Global Market for AML Treatments, by Drug Type, Through 2028
- Table 1 : Global Population, Aged 60+, 2010-2050
- Table 2 : North America, New Patents, 2023
- Table 3 : AML Treatment: Targeted Therapy Drugs
- Table 4 : AML Treatment Cost, by Country
- Table 5 : AML Treatment-related Toxicities and Adverse Effects
- Table 6 : Global COVID-19 Cases, 2023
- Table 7 : Global Market for AML Treatments, by Region, Through 2028
- Table 8 : North American Market for AML Treatments, by Country, Through 2028
- Table 9 : European Market for AML Treatments, by Country, Through 2028
- Table 10 : Asia-Pacific Market for AML Treatments, by Country, Through 2028
- Table 11 : RoW Market for AML Treatments, Through 2028
- Table 12 : Global AML, by Treatment Type, Targeted Therapy
- Table 13 : Global Market for AML Treatments, by Targeted Therapy, Through 2028
- Table 14 : Global Market for AML Treatments, by Anthracycline Drugs, Through 2028
- Table 15 : Global Market for AML Treatments, by Other Chemotherapies, Through 2028
- Table 16 : Global Market for AML Treatments, by IV Administration, Through 2028
- Table 17 : Global AML IV Treatment
- Table 18 : Global AML IV Treatment Cycle
- Table 19 : Global Market for AML Treatments, by Oral Route Administration, Through 2028
- Table 20 : Global AML, Oral Treatment
- Table 21 : Global Market for AML Treatments, by Product, Through 2028
- Table 22 : Global Market for AML Treatments, FLT3 Inhibitors, Through 2028
- Table 23 : Global Market for AML Treatments, Apoptosis Stimulants, Through 2028
- Table 24 : Global Market for AML Treatments, IDH Inhibitors, Through 2028
- Table 25 : Global Market for AML Treatments, Angiogenesis Inhibitors, Through 2028
- Table 26 : Global Market for AML Treatments, DNA Methylation Inhibitors, Through 2028
- Table 27 : Global Market for AML Treatments, DNA Synthesis Inhibitors, Through 2028
- Table 28 : Global Market for AML Treatments, DNA Intercalators, Through 2028
- Table 29 : ESG Framework for the Global Pharmaceutical Industry
- Table 30 : Social Framework, Global Pharmaceutical Industry
- Table 31 : Top Pharma Companies, ESG Ratings
- Table 32 : Global Market for AML Treatments, New Technologies
- Table 33 : Global AML Treatments, by Company Market Share, 2022
- Table 34 : Global AML Treatments, by Product Share, 2022
- Table 35 : Global AML Treatments, by Product Sales, 2022
- Table 36 : Global AML Treatments, Company Information
- Table 37 : Global AML Treatments, Key Financials, 2022
- Table 38 : Patents on AML Drugs, 2018-Present
- Table 39 : Selected Manufacturer Patents on AML Drugs, 2018-Present
- Table 40 : Patents on FLT3 Inhibitors, 2018-Present
- Table 41 : Selected Manufacturer Patents on FLT3 Inhibitors, 2018-Present
- Table 42 : Patents on Apoptosis Stimulants, 2018-Present
- Table 43 : Selected Manufacturer Patents on Apoptosis Stimulants, 2018-Present
- Table 44 : Patents on IDH Inhibitors, 2018-Present
- Table 45 : Selected Manufacturer Patents on IDH Inhibitors, 2018-Present
- Table 46 : Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
- Table 47 : Selected Manufacturer Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
- Table 48 : Patents on DNA Methylation Inhibitor, 2018-Present
- Table 49 : Selected Manufacturer Patents on DNA Methylation Inhibitor, 2018-Present
- Table 50 : Selected Apoptosis Stimulants in Clinical Trials, 2023
- Table 51 : Selected IDH Inhibitors in Clinical Trials, 2023
- Table 52 : Selected IDH Inhibitors in Clinical Trials, 2023
- Table 53 : Selected DNA Methylation Inhibitors in Clinical Trials, 2023.
- Table 54 : Selected FLT3 Inhibitors in Clinical Trials, 2023
- Table 55 : Selected DNA Synthesis Inhibitors in Clinical Trials, 2023
- Table 56 : Global AML Treatment Market: Mergers and Acquisitions, 2019-2022
- Table 57 : AbbVie: Product Information
- Table 58 : AbbVie: Revenue, 2020-2022
- Table 59 : AbbVie: Recent Key Developments
- Table 60 : Amgen: Revenue, 2020-2022
- Table 61 : Amgen: Key Developments, 2021 and 2022
- Table 62 : Astellas Pharma: Revenue, 2020-2022
- Table 63 : Astellas Pharma: Recent Key Developments
- Table 64 : Bayer AG: Marketed Products
- Table 65 : Bayer AG: Annual Revenue, 2020-2022
- Table 66 : Bayer AG: Key Developments, 2022 and 2023
- Table 67 : Biogen: Annual Revenue, 2020-2022
- Table 68 : Biogen: Key Developments, 2018-2023
- Table 69 : Bristol-Myers Squibb: Product Information
- Table 70 : Bristol-Myers Squibb: Revenue, 2020-2022
- Table 71 : Bristol-Myers Squibb: Key Developments, 2020 and 2021
- Table 72 : Daiichi Sankyo: Product Information
- Table 73 : Daiichi Sankyo: Annual Revenue, 2020-2022
- Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
- Table 75 : Gilead Sciences: Annual Revenue, 2020-2022
- Table 76 : Gilead Sciences: Key Developments, 2022 and 2023
- Table 77 : GlaxoSmithKline PLC: Product Segment
- Table 78 : GlaxoSmithKline PLC: Annual Revenue, 2020-2022
- Table 79 : GlaxoSmithKline PLC: Recent Developments, 2022
- Table 80 : Merck & Co. Inc.: Business Segment
- Table 81 : Merck & Co. Inc.: Annual Revenue, 2020-2022
- Table 82 : Merck & Co. Inc.: Key Developments, 2022
- Table 83 : Novartis: Product Information
- Table 84 : Novartis: Revenue, 2020-2022
- Table 85 : Novartis: Key Developments
- Table 86 : Pfizer Inc.: Product Segments
- Table 87 : Pfizer Inc.: Annual Revenue, 2020-2022
- Table 88 : Pfizer Inc.: Top Brands, 2022
- Table 89 : Pfizer Inc.: Key Developments, 2019-2023
- Table 90 : Sanofi: Business Segment
- Table 91 : Sanofi: Annual Revenue, 2020-2022
- Table 92 : Sanofi: Key Developments, 2021-2023
- Table 93 : Servier: Product Information
- Table 94 : Servier: Annual Revenue, 2020-2022
- Table 95 : Servier: Key Developments, 2022 and 2023
- Table 96 : Teva: Financials, 2020-2022
- Table 97 : Teva: Key Developments, 2021-2023
- Table 98 : Acronyms Used in This Report
List of Figures
- Summary Figure A : Global Market for AML Treatments, by Drug Type, 2020-2028
- Summary Figure B : Global Market Shares of AML Treatments, by Drug Type, 2022
- Figure 1 : Global Market Shares of AML Treatments, by Region, 2022
- Figure 2 : North American Market Shares of AML Treatments, by Country, 2022
- Figure 3 : European Market Shares of AML Treatments, by Country, 2022
- Figure 4 : Asia-Pacific Market Shares of AML Treatments, by Country, 2022
- Figure 5 : Global AML Treatment Market Shares, by Drug Type, 2022
- Figure 6 : Global Market Shares of AML Treatments, by Route of Administration, 2022
- Figure 7 : Global Market Shares of AML Treatments, by Oral Route Administration, 2022
- Figure 8 : Global Market Shares of AML Treatments, by Product, Through 2028
- Figure 9 : Global Electricity from Renewable Sources, 2017-2021
- Figure 10 : Global Recycled Waste, 2017-2021
- Figure 11 : Global CO2 Emissions, 2017-2021
- Figure 12 : Global AML Treatments, by Company Market Share, 2022
- Figure 13 : Global AML Treatments, by Product Sales, 2022
- Figure 14 : AbbVie: Market Share, by Country, 2022
- Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country, 2022
- Figure 16 : Daiichi Sankyo: Market Share, by Region/Country, 2022
- Figure 17 : Gilead Sciences: Revenue, by Product, 2022
- Figure 18 : GlaxoSmithKline PLC: Annual Revenue, by Segment, 2020-2022
- Figure 19 : Merck & Co. Inc.: Annual Revenue, by Segment, 2020-2022
- Figure 20 : Novartis Innovative Medicine: Market Share, by Region/Country, 2022
- Figure 21 : Novartis Sandoz: Market Share, by Region/Country, 2022
- Figure 22 : Sanofi: Revenue, by Region/Country, 2022
- Figure 23 : Sanofi: Revenue, by Segment, 2022
- Figure 24 : Teva: Market Share, by Region, 2022
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.